Structural aspects and design of low-molecular-mass complement inhibitors.
about
Compstatin: a complement inhibitor on its way to clinical applicationDesign of a modified mouse protein with ligand binding properties of its human analog by molecular dynamics simulations: the case of C3 inhibition by compstatinNew compstatin variants through two de novo protein design frameworks.Complement-mediated inhibition of neovascularization reveals a point of convergence between innate immunity and angiogenesis.Novel analogues of the therapeutic complement inhibitor compstatin with significantly improved affinity and potency.Identification of new therapeutic targets by genome-wide analysis of gene expression in the ipsilateral cortex of aged rats after stroke.Locally produced complement fragments C5a and C3a provide both costimulatory and survival signals to naive CD4+ T cells.A new generation of potent complement inhibitors of the Compstatin family.New compstatin peptides containing N-terminal extensions and non-natural amino acids exhibit potent complement inhibition and improved solubility characteristicsSpecies specificity of the complement inhibitor compstatin investigated by all-atom molecular dynamics simulationsMolecular dynamics in drug design: new generations of compstatin analogs.Development of complement therapeutics for inhibition of immune-mediated red cell destructionThe proinflammatory mediators C3a and C5a are essential for liver regenerationPeptide redesign for inhibition of the complement system: Targeting age-related macular degeneration.Recent developments in low molecular weight complement inhibitorsNovel compstatin family peptides inhibit complement activation by drusen-like deposits in human retinal pigmented epithelial cell cultures.
P2860
Q24658454-8784C456-EB91-4CEA-90A3-4176E33F5836Q30408033-B576C149-13D3-4C52-8F64-567A6E0DF3A8Q33858609-F08686FE-11F4-4952-B712-A7C4D10F5D51Q34374022-60258AD3-5594-4D66-A357-138B576FEA38Q34459360-BBF655DE-D520-4F8C-BCCA-E4A411D13551Q34516000-A0778601-1495-463F-9E82-929667A1467FQ34760201-328BE9A3-BAE6-4A2B-993F-965374071102Q34984736-D5C00192-C113-4102-A46D-DEF40C0CBC1AQ35013460-A944F80E-C759-4395-8A7C-CFE3BC791B70Q35110256-390C65B7-F897-4B64-955C-1A994AF3DC0AQ35871691-8EB06FCE-B805-4E62-937D-BC80FC5C62EBQ36222203-492DAAB1-5879-4C05-8443-EB9A06ABAB92Q36371713-32C6D1D0-5910-4B59-BF61-4A4FD197F7E0Q37371329-874EA6B8-93E5-4D1B-A5CD-5647287635CAQ37456835-3ECE5E75-A48F-4F5F-85A2-EC6BAF4DD290Q41849353-68FAD955-F81D-4E5A-BD93-8B79BDB89EE5
P2860
Structural aspects and design of low-molecular-mass complement inhibitors.
description
2002 nî lūn-bûn
@nan
2002 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Structural aspects and design of low-molecular-mass complement inhibitors.
@ast
Structural aspects and design of low-molecular-mass complement inhibitors.
@en
type
label
Structural aspects and design of low-molecular-mass complement inhibitors.
@ast
Structural aspects and design of low-molecular-mass complement inhibitors.
@en
prefLabel
Structural aspects and design of low-molecular-mass complement inhibitors.
@ast
Structural aspects and design of low-molecular-mass complement inhibitors.
@en
P356
P1476
Structural aspects and design of low-molecular-mass complement inhibitors.
@en
P2093
P304
P356
10.1042/BST0301026
P577
2002-11-01T00:00:00Z